Skip to main content

Language: English / GĂ idhlig


Chamber and committees

Question ref. S6W-03701
Asked by: Martin Whitfield, South Scotland, Scottish Labour
Date lodged: 12 October 2021


To ask the Scottish Government what action it is taking to improve access to new medicines for people living with progressive forms of MS.

Current status: Answered by Humza Yousaf on 8 November 2021


In December 2019 we published "Neurological Care and Support - a National Framework for Action". Over 5 years we will invest £4.5 million to implement the Framework’s 17 commitments.

Some of these commitments aim to improve access to new medicines for people living with progressive forms of MS, such as our commitment to support the neurological research agenda by promoting the work of the Chief Scientist Office, third sector organisations’ research and Scottish neurological research networks; and encouraging opportunities for people with neurological conditions to become involved in research trials.

In September 2020, the Scottish Medicines Consortium (SMC) accepted siponimod (Mayzent®) for routine use in NHS Scotland. Mayzent® is the first oral Disease Modifying Therapy (DMT) for active secondary progressive MS. The SMC Horizon Scanning Team have also identified several DMT’s in development for the treatment of progressive forms of MS which are predicted to enter the UK market within the next 5 years.